Dofetilide

Dofetilide
Clinical data
Trade names	Tikosyn
AHFS/Drugs.com	Monograph
MedlinePlus	a601235
ATC code	C01BD04 (WHO) ;
Legal status
Legal status	US: WARNING;
Pharmacokinetic data
Bioavailability	96% (oral)
Protein binding	60% -70%
Elimination half-life	10 hours
Identifiers
	IUPAC name N-[4-(2-{[2-(4-methane sulfonamidophenoxy)ethyl] (methyl)amino}ethyl)phenyl]methanesulfonamide;
CAS Number	115256-11-6 ;
PubChem CID	71329;
IUPHAR/BPS	2604;
DrugBank	DB00204 ;
ChemSpider	64435 ;
UNII	R4Z9X1N2ND;
KEGG	D00647 ;
ChEBI	CHEBI:4681 ;
ChEMBL	ChEMBL473 ;
CompTox Dashboard (EPA)	DTXSID5046433 ;
ECHA InfoCard	100.166.441
Chemical and physical data
Formula	C19H27N3O5S2
Molar mass	441.56 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(Nc1ccc(cc1)CCN(CCOc2ccc(cc2)NS(=O)(=O)C)C)C;
	InChI InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3 ; Key:IXTMWRCNAAVVAI-UHFFFAOYSA-N ;
	(verify)

Dofetilide is a class III antiarrhythmic agent.^[2] It is marketed under the trade name Tikosyn by Pfizer, and is available in the United States in capsules containing 125, 250, and 500 μg of dofetilide. It is not available in Europe^[3] or Australia.^[4]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy. 20 (7): 776–786. doi:10.1592/phco.20.9.776.35208. PMID 10907968. S2CID 19897963.
^ Wathion N (2004-04-13). "Public Statement on Tikosyn (dofetilide): Voluntary Withdrawal of the Marketing Authorisation in the European Union" (PDF). European Agency for the Evaluation of Medicinal Products. Archived from the original (PDF) on 2017-10-13. Retrieved 2015-01-03.
^ Australian Medicines Handbook 2014

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[pmid10907968-2] Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy. 20 (7): 776–786. doi:10.1592/phco.20.9.776.35208. PMID 10907968. S2CID 19897963.

[:1-3] Wathion N (2004-04-13). "Public Statement on Tikosyn (dofetilide): Voluntary Withdrawal of the Marketing Authorisation in the European Union" (PDF). European Agency for the Evaluation of Medicinal Products. Archived from the original (PDF) on 2017-10-13. Retrieved 2015-01-03.

[4] Australian Medicines Handbook 2014

[1]

[2]

[3]

[4]